Success Story: A Physician Gets Dual NIW & EB1A Success in Record Time with Premium Processing
Client’s Testimonial:
“Thank you Ms Chen, Ms. Marissa, and Mr. Robert, for the amazing service. It is a long process, and I could not have done it without the professional guidance provided by this amazing team. I am honored to give my strongest recommendation for their service.”
On September 21st, 2025, and September 16th, 2025, we received another I-140 NIW (National Interest Waiver) and EB1A (Alien of Extraordinary Ability) Approvals for a Physician in the Field of Gastroenterology and Oncology (Approval Notice).
General Field: Gastroenterology and Oncology
Position at the Time of Filing: Physician
Country of Origin: Malaysia
State of Residence at the Time of Filing: Washington
Approval Notice Date: September 21st, 2025 & September 16th, 2025 (NIW&EB1A)
Processing Time: 5 days (NIW), and 20 days (EB1A) (Premium Processing Requested)
Case Summary:
We are pleased to announce the approvals of both the I-140 National Interest Waiver (NIW) and the I-140 EB1A (Extraordinary Ability) petitions for our client, a distinguished physician-scientist specializing in gastroenterology and oncology. The NIW petition was approved in September 2024, followed by the EB1A approval in September 2025 through premium processing.
Driving Advances in Gastroenterology and Oncology
With an M.D. degree, the Client has established himself as one of the few leading specialists in pharmacoepidemiology. His work has been particularly impactful in advancing the understanding of messenger ribonucleic acid (mRNA) vaccines and their relationship to gastrointestinal diseases, such as ulcerative colitis flare-ups, as well as gastrointestinal bleeding outcomes in hospital admissions. These investigations hold significant implications for both patient safety and the development of effective therapeutic strategies.
Research Impact and Scholarly Record
The Client has authored 8 peer-reviewed journal articles (1 first-authored) and 24 conference abstracts (7 first-authored), reflecting both his productivity and the originality of his contributions. His body of work has already been cited 180 times, underscoring its relevance and influence among independent researchers in his field. Beyond publications, he has also contributed to the advancement of scientific discourse by conducting at least 8 peer reviews, demonstrating the recognition of his expertise by scholarly journals.
Recognition and Support
The petition was further strengthened by six strong recommendation letters from internationally recognized experts in gastroenterology and related fields. These letters praised the Client’s pioneering research on vaccine impacts and gastrointestinal health and highlighted how his findings are being utilized to guide clinical practices and shape future research.
“In light of his impressive publication record and his significant research achievements, it is clear [Client] occupies a place in the top tier of gastroenterology and oncology.”
National Importance and Funding
The Client’s research directly addresses urgent healthcare priorities by improving understanding of vaccine responses and gastrointestinal disease management, areas with broad implications for U.S. public health. His work exemplifies the kind of innovation needed to strengthen medical practice and enhance patient outcomes nationwide.
A Successful Outcome
The approvals of both the NIW and EB1A petitions affirm the Client’s extraordinary record of success and the national importance of his proposed endeavor. These results are also a testament to NAILG’s careful preparation of the petitions and effective navigation of USCIS’s high evidentiary standards.
We are proud to have assisted the Client through this process and look forward to his continued contributions at the intersection of gastroenterology, oncology, and pharmacoepidemiology, advancing healthcare in ways that will benefit patients across the United States.